The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

The US Food and Drug Administration has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for individuals aged ...

A pending Department of Health and Human Services regulation risks harming public health and stalling innovation.

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The Centers for Disease Control and Prevention (CDC) will no longer recommend that “healthy” children and pregnant women receive the COVID-19 vaccine, Health and Human Services (HHS) Secretary ...

Pfizer suggested that between 15,000 and 20,000 RSV-associated hospitalisations occur ... HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack ...

Moderna (MRNA) stock trades flat as the U.S. cancels a $766M contract granted for the company to develop a vaccine against ...